2328073-61-4

2328073-61-4 structure

Name: ZT-12-037-01
Chemical Name: ZT-12-037-01
CAS Number: 2328073-61-4
Molecular Formula: C₂₁H₃₁N₅O₂
Molecular Weight: 385.50
Catalog: Signaling Pathways GPCR/G Protein Ras
Create Date: 2019-09-09 12:47:51
Modify Date: 2024-02-03 12:44:27
ZT-12-037-01 is a STK19-targeted inhibitor, has a high-affinity interaction with STK19 protein and inhibits oncogenic NRAS-driven melanocyte malignant transformation. ZT-12-037-01 is an ATP-competitive inhibitor, inhibiting phosphorylation of NRAS (major isoform of Ras family) with an IC50 of 24 nM[1].

Name	ZT-12-037-01

Description	ZT-12-037-01 is a STK19-targeted inhibitor, has a high-affinity interaction with STK19 protein and inhibits oncogenic NRAS-driven melanocyte malignant transformation. ZT-12-037-01 is an ATP-competitive inhibitor, inhibiting phosphorylation of NRAS (major isoform of Ras family) with an IC50 of 24 nM[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> GPCR/G Protein >> Ras
In Vitro	ZT-12-037-01 (3 μM; 14 days) significantly inhibits mutant NRAS-STK19-driven melanocyte colony formation and proliferation[1]. ZT-12-037-01 (0-3 μM) has an inhibitory effects of ZT-12-037-01 on STK19WT and STK19D89N-activated NRAS phosphorylation in HPMs[1]. Cell Proliferation Assay[1] Cell Line: CDK4 (R24C) melanocyte cells; hTERT melanocyte cells; p53DD melanocyte cells Concentration: 3 μM Incubation Time: 14 days Result: Inhibited melanocyte proliferation. Western Blot Analysis[1] Cell Line: STK19WT and STK19D89N Concentration: 0 μM, 0.1 μM, 0.3 μM, 1 μM, 3 μM Incubation Time: Result: Inhibited NRAS phosphorylation.
In Vivo	ZT-12-037-01 (injection subcutaneously; 25-50 mg/kg; once daily; 21 days) inhibits growth of SK-MEL-2 xenograft melanoma and the sections of tumors indicates induction of apoptosis by increasing cleaved caspase-3[1]. Animal Model: SK-MEL-2 xenograft melanoma nude mice with hTERT/p53DD/CDK4(R24C) melanocytes[1] Dosage: 25 mg/kg; 50 mg/kg Administration: Injected subcutaneously; 21 days Result: Inhibited growth of SK-MEL-2 xenograft melanoma.
References	[1]. Yin C, et al. Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis. Cell. 2019 Feb 21;176(5):1113-1127.e16.

Molecular Formula	C₂₁H₃₁N₅O₂
Molecular Weight	385.50

2328073-61-4	85416-30-4
824404-29-7	115532-07-5
56927-05-0	35514-05-7
37234-62-1	134765-72-3
79894-08-9	87893-54-7
2138438-44-3	1158522-08-7
2229253-63-6	940364-43-2
2228338-05-2	134104-43-1
131615-57-1	6906-52-1
930439-75-1	2229341-92-6